Nature Reviews Drug Discovery integrates academia and industry, providing broad, expert coverage of the whole drug discovery and development arena – from disease mechanisms, novel therapeutic approaches and chemistry to clinical trials and regulatory affairs. All reviews are carefully commissioned, written by leaders in the field and subject to rigorous peer-review so that readers receive independent, high-quality and authoritative articles in each issue. Reviews are complemented by news stories that investigate the key issues in drug discovery, timely summaries of significant published papers, market analysis, and updates on the latest advances in fast-moving areas such as new technologies, drug approvals and patent law. Information is presented at several levels that can be tailored to users’ individual needs. Non-specialists will benefit from the glossary and highlighted references, and experts will appreciate the insight provided by top names in their field. Nature Reviews Drug Discovery is a major teaching and reference resource from NPG. http://feeds.nature.com/nrd/rss/current Nature Publishing Group en © 2024 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Nature Reviews Drug Discovery © 2024 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. [email protected] https://www.nature.com/uploads/product/nrd/rss.gif http://feeds.nature.com/nrd/rss/current https://www.nature.com/articles/s41573-024-00974-9 Nature Reviews Drug Discovery, Published online: 01 July 2024; doi:10.1038/s41573-024-00974-9

In situ cancer vaccines generate tumour-specific T cell responses and hold promise for the treatment of solid tumours. This Review discusses drug delivery technologies such as lipid nanoparticles, hydrogels and scaffolds that are being developed to boost the antitumour immune effects of several types of in situ cancer vaccine.]]> Ningqiang GongMohamad-Gabriel AlamehRakan El-MaytaLulu XueDrew WeissmanMichael J. Mitchell doi:10.1038/s41573-024-00974-9 Nature Reviews Drug Discovery, Published online: 2024-07-01; | doi:10.1038/s41573-024-00974-9 2024-07-01 Nature Reviews Drug Discovery 10.1038/s41573-024-00974-9 https://www.nature.com/articles/s41573-024-00974-9 https://www.nature.com/articles/d41573-024-00111-6 Nature Reviews Drug Discovery, Published online: 27 June 2024; doi:10.1038/d41573-024-00111-6

Machine learning identifies AMPs]]> Sarah Crunkhorn doi:10.1038/d41573-024-00111-6 Nature Reviews Drug Discovery, Published online: 2024-06-27; | doi:10.1038/d41573-024-00111-6 2024-06-27 Nature Reviews Drug Discovery 10.1038/d41573-024-00111-6 https://www.nature.com/articles/d41573-024-00111-6 https://www.nature.com/articles/d41573-024-00112-5 Nature Reviews Drug Discovery, Published online: 27 June 2024; doi:10.1038/d41573-024-00112-5

Discovering CFTR modulators]]> Sarah Crunkhorn doi:10.1038/d41573-024-00112-5 Nature Reviews Drug Discovery, Published online: 2024-06-27; | doi:10.1038/d41573-024-00112-5 2024-06-27 Nature Reviews Drug Discovery 10.1038/d41573-024-00112-5 https://www.nature.com/articles/d41573-024-00112-5 https://www.nature.com/articles/d41573-024-00110-7 Nature Reviews Drug Discovery, Published online: 27 June 2024; doi:10.1038/d41573-024-00110-7

ETS2 drives IBD]]> Sarah Crunkhorn doi:10.1038/d41573-024-00110-7 Nature Reviews Drug Discovery, Published online: 2024-06-27; | doi:10.1038/d41573-024-00110-7 2024-06-27 Nature Reviews Drug Discovery 10.1038/d41573-024-00110-7 https://www.nature.com/articles/d41573-024-00110-7 https://www.nature.com/articles/d41573-024-00113-4 Nature Reviews Drug Discovery, Published online: 27 June 2024; doi:10.1038/d41573-024-00113-4

A selective microbiome-sparing antibiotic]]> Sarah Crunkhorn doi:10.1038/d41573-024-00113-4 Nature Reviews Drug Discovery, Published online: 2024-06-27; | doi:10.1038/d41573-024-00113-4 2024-06-27 Nature Reviews Drug Discovery 10.1038/d41573-024-00113-4 https://www.nature.com/articles/d41573-024-00113-4 https://www.nature.com/articles/d41573-024-00114-3 Nature Reviews Drug Discovery, Published online: 27 June 2024; doi:10.1038/d41573-024-00114-3

Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca, discusses her chronic disease research priorities, including the need for new diagnostic tools, fixed-dose drugs and a better understanding of disease biology.]]> Asher Mullard doi:10.1038/d41573-024-00114-3 Nature Reviews Drug Discovery, Published online: 2024-06-27; | doi:10.1038/d41573-024-00114-3 2024-06-27 Nature Reviews Drug Discovery 10.1038/d41573-024-00114-3 https://www.nature.com/articles/d41573-024-00114-3 https://www.nature.com/articles/d41573-024-00109-0 Nature Reviews Drug Discovery, Published online: 25 June 2024; doi:10.1038/d41573-024-00109-0

Jude Samulski, former CSO and co-founder of AskBio, discusses the future of gene therapy for complex and common diseases, including Parkinson disease and congestive heart failure.]]> Asher Mullard doi:10.1038/d41573-024-00109-0 Nature Reviews Drug Discovery, Published online: 2024-06-25; | doi:10.1038/d41573-024-00109-0 2024-06-25 Nature Reviews Drug Discovery 10.1038/d41573-024-00109-0 https://www.nature.com/articles/d41573-024-00109-0 https://www.nature.com/articles/d41573-024-00108-1 Nature Reviews Drug Discovery, Published online: 21 June 2024; doi:10.1038/d41573-024-00108-1

FDA approves 21-valent pneumococcal vaccine]]> Asher Mullard doi:10.1038/d41573-024-00108-1 Nature Reviews Drug Discovery, Published online: 2024-06-21; | doi:10.1038/d41573-024-00108-1 2024-06-21 Nature Reviews Drug Discovery 10.1038/d41573-024-00108-1 https://www.nature.com/articles/d41573-024-00108-1